So Jung Lim

Title: Innovations of So Jung Lim in Cancer Therapy

Introduction

So Jung Lim is an accomplished inventor based in Yongin-si, South Korea. He has made significant contributions to the field of biomedical research, particularly in the development of therapeutic agents for cancer treatment. His innovative work focuses on bispecific antibodies, which have the potential to revolutionize cancer therapy.

Latest Patents

So Jung Lim holds a patent for a bispecific antibody specifically binding to GPNMB and CD3. This antibody demonstrates high affinity and specificity to both CD3 (cluster of differentiation 3) and GPNMB (glycoprotein non-metastatic melanoma protein B). The patent outlines the use of this bispecific antibody to induce death in cancer cells expressing GPNMB while inhibiting their proliferation. This innovation positions the bispecific antibody as an effective therapeutic agent for cancers that express GPNMB.

Career Highlights

Throughout his career, So Jung Lim has worked with notable organizations, including the Green Cross Corporation and Mogam Institute for Biomedical Research. His experience in these institutions has allowed him to advance his research and contribute to the development of innovative cancer therapies.

Collaborations

So Jung Lim has collaborated with several professionals in his field, including Jae Chan Park and Eun Jung Song. These collaborations have further enriched his research and development efforts in the biomedical sector.

Conclusion

So Jung Lim's work in developing bispecific antibodies represents a significant advancement in cancer therapy. His innovative approach has the potential to improve treatment outcomes for patients with cancers expressing GPNMB.